Eszopiclone Tablets launched in US market
Dr Reddy's Laboratories announced that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA).
The LUNESTA (eszopiclone) tablets C-IV brand and generic combined had U.S. sales of approximately $887 Million MAT for the most recent twelve months ending in January 2014 according to IMS Health*.
Dr Reddy's Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100